# US 2015/0104413 A1 · Immunogenic wt-1 peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104413 A1
- Document ID: US20150104413A1
- Status: Published application
- Kind: A1
- Application number: 14/372,174
- Filed: 2013-01-14
- Published: 2015-04-16
- Earliest claimed: 2012-01-13
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Richard J. O'Reilly; Ekaterina Doubrovina; Annamalai Selvakumar
- Web page: https://patentgrep.com/patent/US20150104413A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 39/001153: {Wilms tumor 1 [WT1]}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 7/06: having 5 to 11 amino acids
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55527: {Interleukins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/55594: {from bacteria}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein.

## Claims

### Claim 1

An isolated WT-1 peptide consisting ofan amino acid sequence selected from among AILDFLLLQ (SEQ ID NO:147), RQRPHPGAL (SEQ ID NO:142), GALRNPTAC (SEQ ID NO:143), THSPTHPPR (SEQ ID NO:146), ASGSEPQQM (SEQ ID NO:151), WNQMNLGATLK (SEQ ID NO:173), PGCLQQPEQQG (SEQ ID NO:149), and LDFAPPGASAY (SEQ ID NO:156).

### Claim 2

An isolated WT-1 peptide consisting ofan amino acid sequence selected from among PLPHFPPSL (SEQ ID NO:144), HFPPSLPPT (SEQ ID NO:145), PGCLQQPEQ (SEQ ID NO:148), KLGAAEASA (SEQ ID NO:150), LLAAILDFL (SEQ ID NO:184), CLQQPEQQGV (SEQ ID NO:185) and ALRNPTACPL (SEQ ID NO:191).

### Claim 3

An isolated WT-1 peptide consisting of an amino acid sequence selected from amongRDLNALLPAV (SEQ ID NO:152), GGCALPVSGA (SEQ ID NO:153), GAAQWAPVL (SEQ ID NO:154), LDFAPPGAS (SEQ ID NO:155), SAYGSLGGP (SEQ ID NO:157), PAPPPPPPP (SEQ ID NO:158), ACRYGPFGP (SEQ ID NO:159), SGQARMFPN (SEQ ID NO:160), PSCLESQPA (SEQ ID NO:162), NQGYSTVTF (SEQ ID NO:163), HHAAQFPNH (SEQ ID NO:164), HSFKHEDPM (SEQ ID NO:165), CHTPTDSCT (SEQ ID NO:166), CTGSQALLL (SEQ ID NO:167), TDSCTGSQA (SEQ ID NO:168), RTPYSSDNL (SEQ ID NO:169), NLYQMTSQLE (SEQ ID NO:170), WNQMNLGAT (SEQ ID NO:171), WNQMNLGATLK (SEQ ID NO:173), CMTWNQMNLGATLKG (SEQ ID NO:174), NLGATLKGV (SEQ ID NO:175), LGATLKGVAA (SEQ ID NO:176), TLGVAAGS (SEQ ID NO:177), GYESDNHTT (SEQ ID NO:178), FMCAYPGCNK (SEQ ID NO:179), KRPFMCAYPGC (SEQ ID NO:180), RKFSRSDHL (SEQ ID NO:181), LKTHTTRTHT (SEQ ID NO:182), NMHQRNHTKL (SEQ ID NO:183), QARMFPNAPY (SEQ ID NO:190), ALRNPTACPL (SEQ ID NO:191) and APVLDFAPPGASAYG (SEQ ID NO:193).

### Claim 4

An isolated WT-1 peptide consisting ofan amino acid sequence selected from among SEQ ID NO:1-141.

### Claim 5

An isolated WT-1 peptide consisting of 8-30 amino acids comprising an amino acid sequence selected from SEQ ID NO: 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 184 and 185.

### Claim 6

An isolated WT-1 peptide consisting of 16-30 amino acids comprising an amino acid sequence selected from SEQ ID NO:1-141.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The isolated WT-1 peptide of any one of claims 1-6, wherein said isolated WT-1 peptide binds to an HLA class I molecule, an HLA class II molecule, or the combination thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising a peptide of any one of claims 1-6 and a pharmaceutically acceptable carrier, vehicle or excipient.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A vaccine comprising (a) one or more isolated WT-1 peptides of claims 1-6 and (b) an adjuvant or a carrier.

### Claim 10 (depends on 9)

The vaccine of claim 9, wherein said adjuvant is QS21, Freund's incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanideor GM-CSF.

### Claim 11 (depends on 9)

A method of treating a subject with a WT-1-expressing cancer or reducing an incidence of a WT-1-expressing cancer, or its relapse, the method comprising administering to said subject the vaccine of claim 9, thereby treating a subject with a WT-1-expressing cancer, reducing an incidence of a WT-1-expressing cancer or its relapse therein.

### Claim 12 (depends on 11)

The method of claim 11, wherein said WT-1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), or a non-small cell lung cancer (NSCLC).

### Claim 13 (depends on 9)

A method of inducing the formation and proliferation of CTL specific for cells of a WT-1-expressing cancer, the method comprising administering to said subject the vaccine of claim 9, thereby inducing the formation and proliferation of CTL specific for cells of a WT-1-expressing cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein said WT-1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), or a non-small cell lung cancer (NSCLC).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6)

A composition comprising (a) an antigen-presenting cell and (b) a peptide of any one of claims 1-6.

### Claim 16 (depends on 11, 12, 13, 14)

The method of any one of claims 11-14 wherein the cancer is mesothelioma.
